Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Norwegian (OSEAX) Healthcare Sector Analysis

UpdatedJun 07, 2026
DataAggregated Company Financials
Companies21
  • 7D-2.2%
  • 3M1.6%
  • 1Y-9.0%
  • YTD-11.9%

Over the last 7 days, the Healthcare industry has dropped 2.2%, and Thor Medical contributed the most with a 11% decline. The industry has fallen 9.0% in the last year. Looking forward, earnings are forecast to grow by 26% annually.

Sector Valuation and Performance

Has the Norwegian Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 08 Jun 2026NOK 16.9bNOK 3.9b-NOK 636,110,833.6122.9x-26.6x4.3x
Wed, 06 May 2026NOK 17.1bNOK 3.7b-NOK 503,112,311.8539x-34.1x4.6x
Fri, 03 Apr 2026NOK 16.9bNOK 3.7b-NOK 574,139,180.7035x-29.4x4.6x
Sun, 01 Mar 2026NOK 16.9bNOK 3.7b-NOK 634,032,993.6637.6x-26.7x4.6x
Tue, 27 Jan 2026NOK 18.2bNOK 3.7b-NOK 603,901,630.1631.3x-30.1x4.9x
Thu, 25 Dec 2025NOK 18.4bNOK 3.7b-NOK 608,706,270.1233.4x-30.2x4.9x
Sat, 22 Nov 2025NOK 16.0bNOK 3.4b-NOK 812,016,646.1747.7x-19.7x4.8x
Mon, 20 Oct 2025NOK 16.9bNOK 3.6b-NOK 716,497,904.5425.6x-23.5x4.6x
Wed, 17 Sep 2025NOK 17.4bNOK 3.6b-NOK 694,785,704.9227.1x-25.1x4.8x
Fri, 15 Aug 2025NOK 17.8bNOK 3.9b-NOK 1,052,421,955.6023.3x-16.9x4.6x
Sun, 13 Jul 2025NOK 17.0bNOK 3.9b-NOK 1,042,582,883.8825.6x-16.3x4.4x
Tue, 10 Jun 2025NOK 16.8bNOK 3.9b-NOK 1,055,440,442.0827.5x-16x4.3x
Thu, 08 May 2025NOK 16.0bNOK 3.5b-NOK 1,213,836,819.2122x-13.2x4.6x
Sat, 05 Apr 2025NOK 15.2bNOK 3.5b-NOK 1,231,798,951.2416.7x-12.3x4.4x
Mon, 03 Mar 2025NOK 16.2bNOK 3.4b-NOK 1,216,965,488.6918.5x-13.3x4.7x
Wed, 29 Jan 2025NOK 16.4bNOK 3.8b-NOK 1,104,971,449.2324.8x-14.8x4.4x
Fri, 27 Dec 2024NOK 16.0bNOK 3.8b-NOK 1,106,206,600.9724.9x-14.4x4.3x
Sun, 24 Nov 2024NOK 16.6bNOK 4.0b-NOK 980,024,949.4323.3x-17x4.1x
Tue, 22 Oct 2024NOK 17.2bNOK 4.0b-NOK 928,008,117.8720.1x-18.5x4.3x
Thu, 19 Sep 2024NOK 18.3bNOK 4.0b-NOK 957,100,911.1419.1x-19.1x4.6x
Sat, 17 Aug 2024NOK 21.2bNOK 4.0b-NOK 960,469,043.3617.3x-22.1x5.3x
Mon, 15 Jul 2024NOK 21.9bNOK 4.0b-NOK 969,507,281.8616.9x-22.6x5.5x
Wed, 12 Jun 2024NOK 23.0bNOK 4.2b-NOK 1,133,387,313.9917.6x-20.3x5.4x
Fri, 10 May 2024NOK 21.7bNOK 4.2b-NOK 1,146,116,759.9617.9x-18.9x5.1x
Sun, 07 Apr 2024NOK 22.0bNOK 4.2b-NOK 1,114,344,892.3328.8x-19.7x5.3x
Tue, 05 Mar 2024NOK 25.9bNOK 4.2b-NOK 1,153,410,644.3527.9x-22.4x6.2x
Thu, 01 Feb 2024NOK 29.9bNOK 4.1b-NOK 1,590,183,018.0023.9x-18.8x7.3x
Sat, 30 Dec 2023NOK 30.4bNOK 4.1b-NOK 1,572,810,500.0023.2x-19.3x7.5x
Mon, 27 Nov 2023NOK 28.2bNOK 4.1b-NOK 1,587,922,222.0021.7x-17.8x6.9x
Wed, 25 Oct 2023NOK 26.2bNOK 3.4b-NOK 1,899,679,218.0033x-13.8x7.6x
Fri, 22 Sep 2023NOK 28.8bNOK 3.6b-NOK 1,812,467,538.0033.6x-15.9x8.1x
Sun, 20 Aug 2023NOK 28.3bNOK 3.5b-NOK 1,849,937,079.0032.7x-15.3x8.2x
Tue, 18 Jul 2023NOK 28.7bNOK 3.4b-NOK 1,813,141,485.0030.3x-15.8x8.5x
Thu, 15 Jun 2023NOK 29.4bNOK 3.4b-NOK 1,839,282,426.0043x-16x8.7x
Price to Earnings Ratio

-16x


Total Market Cap: NOK 29.4bTotal Earnings: -NOK 1,839,282,426.00Total Revenue: NOK 3.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Norwegian Healthcare Sector Price to Earnings3Y Average -20.1x202420252026
Current Industry PE
  • Investors are pessimistic on the Norwegian Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 5.4x is higher than the industry's current PS ratio of 4.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have improved over the last three years.
  • Revenues for these companies have grown 4.9% per year.
  • This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.

Industry Trends

Which industries have driven the changes within the Norwegian Healthcare sector?

NO Market0.24%
Healthcare-2.19%
Healthcare Services5.85%
Medical Equipment1.75%
Pharma-2.96%
Biotech-4.34%
Healthtech-5.64%
Industry PE
    Forecasted Growth
    • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 74% over the next 5 years.
    • This is better than its past earnings decline of 64% per year.
    • In contrast, the Pharma industry is expected to see its earnings grow by 5.6% per year over the next few years.

    Top Stock Gainers and Losers

    Which companies have driven the market over the last 7 days?

    CompanyLast Price7D1YValuation
    		MEDI MedistimNOK 232.001.8%
    +NOK 73.2m    		12.1%PE27.2x
    		NYKD Nykode TherapeuticsNOK 3.253.7%
    +NOK 37.6m    		89.0%PS201.7x
    		SOFTX SoftOx SolutionsNOK 0.1212.6%
    +NOK 35.8m    		54.1%PS20.5x
    		ZLNA ZellunaNOK 22.905.5%
    +NOK 31.5m    		63.6%PS75197.3x
    		INIFY INIFY LaboratoriesNOK 5.255.8%
    +NOK 31.2m    		-19.2%n/a

    Latest News

    PHO
    NOK 58.90
    Photocure
    7D
    -5.0%
    1Y
    14.4%
    SOFTX
    NOK 0.12
    SoftOx Solutions
    7D
    12.6%
    1Y
    54.1%
    AZT
    NOK 20.80
    ArcticZymes Technologies
    7D
    -7.6%
    1Y
    29.6%
    LYTIX
    NOK 9.92
    Lytix Biopharma
    7D
    -6.0%
    1Y
    15.3%
    Analysis Article • Jun 02

    We're Hopeful That Lytix Biopharma (OB:LYTIX) Will Use Its Cash Wisely

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
    VISTN
    NOK 20.40
    Vistin Pharma
    7D
    -2.9%
    1Y
    -15.7%
    MEDI
    NOK 232.00
    Medistim
    7D
    1.8%
    1Y
    12.1%
    Narrative Update • May 25

    MEDI: Clinical Trial Momentum And Dividend Visibility Will Support Future Performance

    Analysts have kept Medistim's fair value estimate steady at NOK 315.0. This reflects slightly updated assumptions on discount rate, revenue growth, profit margin and future P/E, without a change in their overall price target stance. What's in the News Medistim ASA plans a board meeting on February 26, 2026, to consider and resolve the annual general meeting and an ordinary dividend for 2025 (company announcement).
    NORDH
    NOK 25.40
    Nordhealth
    7D
    -7.3%
    1Y
    -37.1%
    NAVA
    NOK 16.80
    Navamedic
    7D
    -4.8%
    1Y
    -24.3%
    NYKD
    NOK 3.25
    Nykode Therapeutics
    7D
    3.7%
    1Y
    89.0%
    New Narrative • May 19

    Head And Neck Cancer Trial Progress And Cash Runway Will Support Long Term Potential

    Catalysts About Nykode Therapeutics Nykode Therapeutics is a biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?
    CODE
    NOK 3.16
    CodeLab Capital
    7D
    12.9%
    1Y
    10.1%
    CRNA
    NOK 8.42
    Circio Holding
    7D
    -6.4%
    1Y
    1,149.3%
    TRMED
    NOK 4.14
    Thor Medical
    7D
    -10.9%
    1Y
    62.5%
    HBC
    NOK 1.32
    Hofseth BioCare
    7D
    4.8%
    1Y
    -37.7%
    INIFY
    NOK 5.25
    INIFY Laboratories
    7D
    5.8%
    1Y
    -19.2%
    ZLNA
    NOK 22.90
    Zelluna
    7D
    5.5%
    1Y
    63.6%
    OBSRV
    NOK 1.13
    Observe Medical
    7D
    11.9%
    1Y
    0.4%